BrainStorm Cell Therapeutics, Inc. (BCLI.OB) Announces Superior Stem Cell Treatments
QualityStocks (November 9th, 2009) Writes:
Today, BrainStorm Cell Therapeutics Inc. took the opportunity to announce that the company’s therapeutic treatment for neurodegenerative diseases displayed superior results to other current potential stem cell treatments in a recently conducted study.
The Israel Medical Association Journal published a scientific paper, authored by Ofer Sadan, Eldad Melamed and Daniel Offen from Tel Aviv University, showing the migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models of Parkinson’s and Huntington diseases. The study demonstrated that in a rat model for Parkinson’s disease, the efficacy of NTF-SC was superior in behavior, biochemical and histological indices to that of mesenchymal stem cells. The complete study and scientific paper are available on Brainstorm’s website at http://www.brainstorm-cell.com/_Uploads/47Sadan2009.pdf.
Professor Daniel Offen, Brainstorm’s chief scientific advisor, commented, “The results of this study show that the NTF-SC based treatment is efficacious due to NTF secretion and the stem cell’s migratory capabilities. Since our novel technology
...Brainstorm Cell Therapeutics Inc.;, cell therapy, ceo, Chief Scientific Advisor, Daniel Offen, Eldad Melamed, Investing Lessons, Israel Medical Association Journal, neurodegenerative diseases, Ofer Sadan, Professor, Rami Efrati, Small & Micro Cap, Stem Cells, Tel-Aviv University;, The Israel Medical Association Journal, transplantation, treatment for neurodegenerative diseases, treatment of neurodegenerative diseases


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)



